LTR Pharma Limited (LTP.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.44 (+0.00%) as of
Key statistics
- Market cap
- 80.20M
- EPS (TTM)
- -0.0800
- Dividend yield
- 0.00%
- 52-week range
- 0.3500 – 0.7500
- Beta
- 2.20
- Revenue (TTM)
- 723.93k
- Profit margin
- 0.00%
- Volume
- 49.24k
About LTR Pharma Limited
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Brisbane, QLD, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.